Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis

Inflammopharmacology

Volumn 20, Issue 1, 2012, Pages 1-18

  Thomas, Saskia ^a   Baumgart, Daniel C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Adhesion; Chemokines; Crohn's disease; Dendritic cells; IBD; Immunoglobulin superfamily cellular adhesion molecules; Inflammatory bowel disease; Integrins; Leukocytes; Migration; Recruitment; T cells; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AJM 300; ALICAFORSEN; ANTIINFLAMMATORY AGENT; CCX 282; CCX 282 B; CHEMOKINE RECEPTOR CCR ANTAGONIST; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; ETROLIZUMAB; FIBRONECTIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GSK 1605786; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; MESALAZINE; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PLACEBO; RANTES; STEROID; TRAFICET EN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; DENDRITIC CELL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; GRANULOCYTE; HUMAN; INJECTION SITE REACTION; INTESTINE MUCOSA; LAMINA PROPRIA; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MONOCYTE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; SIDE EFFECT; TH1 CELL; TH17 CELL; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ANIMAL; CELL ADHESION; CELL MOTION; IMMUNOLOGY; LEUKOCYTE; PATHOLOGY;

ANIMALS; CELL ADHESION; CELL MOVEMENT; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES;

EID: 84861318436     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-011-0104-6     Document Type: Review

References (135)

1. Agace WW (2006) Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 6:682-692.
2. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hebuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, Van AG, Rutgeerts P, Lemann M, Colombel JF (2010) The efficacy and safety of a third anti- TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 31:92-101.
3. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, Agace WW, Parker CM, Powrie F (2005) Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 202:1051-1061.
4. Aranda R, Sydora BC, McAllister PL, Binder SW, Yang HY, Targan SR, Kronenberg M (1997) Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4?, CD45RBhigh T cells to SCID recipients. J Immunol 158:3464-3473.
5. Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339:269-280.
6. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627-1640.
7. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641-1657.
8. Bekker P, Velde A, Pronk I, Keshav S, Hommes D, Hanauer S, Ungashe S, Zheng W, Wright K, Schall T (2007) Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease. Inflamm Bowel Dis 13:647.
9. Bekker P, Petryka R, Vanasek T, Niv Y, Marlicz K, Haagen-Nielsen O, Dahelrup J, Dotan I, Compel V, Keshav S, Schall TJ (2008) PROTECT-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial. Inflamm Bowel Dis 14(1):S11.
10. Bekker P, Keshav S, Johnson D, Schall TJ (2009) PROTECT-1 maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Inflamm Bowel Dis 15(12):S11.
11. Berlin C, Bargatze RF, Campbell JJ, von Andrian UH, Szabo MC, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC (1995) Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80:413-422.
12. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T (2008) Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111:3439-3441.
13. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ (1997) Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 151:97-110.
14. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60-66.
15. Cellier C, Cervoni JP, Patey N, Barbier JP, Brousse N (1997) Cellular adherence and chronic inflammatory bowel diseases. Gastroenterol Clin Biol 21:832-842.
16. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621.
17. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, Kang DY, Wolf RE, Grisham MB (1997) Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 282:1615-1622.
18. Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127-159.
19. del Pilar MM, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stuve O (2008) Decrease in the numbers of dendritic cells and CD4? T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65:1596-1603.
20. Delves PJ, Roitt IM (2000a) The immune system. First of two parts. N Engl J Med 343:37-49.
21. Delves PJ, Roitt IM (2000b) The immune system. Second of two parts. N Engl J Med 343:108-117.
22. Dietz SB, Whitaker-Menezes D, Lessin SR (1996) The role of alpha E beta 7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. J Cutan Pathol 23:312-318.
23. Eksteen B, Adams DH (2010) GSK-1605786, a selective smallmolecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. Idrugs 13(7):472-481.
24. Eksteen B, Miles AE, Grant AJ, Adams DH (2004) Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med 4:173-180.
25. Elewaut D, Van DN, De KF, Baeten D, De PP, Van VH, Mielants H, Cuvelier C, Verbruggen G, Veys EM, De VM (1998) Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg 61:288-294.
26. Engelhardt B (1998) The role of alpha 4-integrin in T lymphocyte migration into the inflamed and noninflamed central nervous system. Curr Top Microbiol Immunol 231:51-64.
27. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, Hoch G (1998) The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 102:2096-2105.
28. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Cohen A, Bitton A, Baker J, Dube R, Landau SB, Vandervoort MK, Parikh A (2008) Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4- beta7 integrin. Clin Gastroenterol Hepatol 6:1370-1377.
29. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352:2499-2507.
30. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:108-115.
31. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S (2003) Natalizumab for active Crohn's disease. N Engl J Med 348:24-32.
32. GlaxoSmithKline (2010a) A randomised, double-blind, placebocontrolled study to investigate the efficacy and safety of GSK1605786A in the treatment of subjects with moderatelyto- severely active Crohn's disease. GlaxoSmithKline Clinical study register. http://www.gsk-clinicalstudyregister.com/protocol- detail.jsp?protocolId=114151&studyId=AFAB9F92-BD7D-4519-AE97- 0B338AEB0A37&compound=Gsk1605786&type=compound&letterrange=G-K. Accessed 1 December 2010.
33. GlaxoSmithKline (2010b) A single dose, randomized, five-period crossover study to assess the relative bioavailability of four new formulations of the CCR9 receptor antagonist GSK1605786A (CCX282) in healthy male and female subjects. GlaxoSmithKline Clinical study register. http://www.gsk- clinicalstudyregister.com/protocol-detail.jsp?protocolId=114203&studyId= 1849C81DAE7C-47E9-AA94-E140D1E35784&compound=Gsk1605786&type= compound&letterrange=G-K. Accessed 1 May 2010.
34. GlaxoSmithKline (2011) A 52 week randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GSK1605786A in the maintenance of remission in subjects with Crohn's disease. GlaxoSmithKline Clinical study register. http://www.gsk-clinicalstudyregister. com/protocol-detail.jsp?protocolId=114157&studyId=A138BB5F-6BDC-4BB7- 9BECBD1968A8E986&compound=Gsk1605786&type=compound&letterrange=G-K Accessed 1 April 2011.
35. Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR Jr (1997) Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
36. Gonzalez-Amaro R, Mittelbrunn M, Sanchez-Madrid F (2005) Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? Immunology 116:289-296.
37. Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE (2002) A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16:699-705.
38. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121:268-274.
39. Handel TM, Domaille PJ (1996) Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35:6569-6584.
40. Henninger DD, Panes J, Eppihimer M, Russell J, Gerritsen M, Anderson DC, Granger DN (1997) Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 158:1825-1832.
41. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, Newman W, Ringler DJ (1996) Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 111:1373- 1380.
42. Hetzel DJ, Badov D, Connell W, Edwards S, Gibson PR, Leong R, Macrae F, Mitchell B, Radford-Smith G, Bekker P, Schall TJ (2009) CCX282-B (TRAFICET-EN (TM)), a chemokine receptor CCR9 selective antagonist, is an effective treatment for patients with moderate to severe Crohn's disease. J Gastroenterol Hepatol 24:A312-A313.
43. Humphries MJ (1990) The molecular basis and specificity of integrinligand interactions. J Cell Sci 97(Pt 4):585-592.
44. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687.
45. Iliev ID, Matteoli G, Rescigno M (2007) The yin and yang of intestinal epithelial cells in controlling dendritic cell function. J Exp Med 204:2253-2257.
46. Ito H, Kihara H, Andou A, Ejima C, Ono M, Tanaka Y, Suzuki M, Murata M (2005) Oral treatment with novel alpha4 integrin blocker, AJM300, is efficacious in a rat model of DNBS-induced colitis. Gastroenterology 128:A200.
47. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, Berg PL, Davidsson T, Powrie F, Johansson-Lindbom B, Agace WW (2008) Small intestinal CD103? dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 205:2139-2149.
48. Kato S, Hokari R, Matsuzaki K, Iwai A, Kawaguchi A, Nagao S, Miyahara T, Itoh K, Ishii H, Miura S (2000) Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 295:183-189.
49. Kawachi S, Jennings S, Panes J, Cockrell A, Laroux FS, Gray L, Perry M, van der HH, Balish E, Granger DN, Specian RA, Grisham MB (2000) Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 278:G734-G743.
50. Keshav S, Petryka R, Vanask T, Niv Y, Marlicz K, Haagen-Nielsen O, Machado M, Dahlerup J, Sschreiber S, Bekker P, Sankar S, Schall TJ (2007a) PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease. Am J Gastroenterol 102:S475.
51. Keshav S, Ungashe S, Zheng W, Belker P, Wright K, Schall TJ (2007b) Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease. Gastroenterology 132:A157.
52. Keshav S, Johnson D, Bekker P, Schall TJ (2009) PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate to severe Crohn's disease. Gastroenterology 136(5):A65.
53. Kim CH, Broxmeyer HE (1999) Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 65:6-15.
54. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369-374.
55. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK (1992) Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 103:840-847.
56. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Pan GD (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546-551.
57. Kroneld U, Jonsson R, Carlsten H, Bremell T, Johannessen AC, Tarkowski A (1998) Expression of the mucosal lymphocyte integrin alphaEbeta7 and its ligand E-cadherin in salivary glands of patients with Sjogren's syndrome. Scand J Rheumatol 27:215-218.
58. Kunkel EJ, Campbell DJ, Butcher EC (2003) Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 10:313-323.
59. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381.
60. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK, Baird LG, Erikson M, Colvin RB (1984) Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 133:1857-1862.
61. Lee TW, Fedorak RN (2010) Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 39:543-557.
62. Lefrancois L, Parker CM, Olson S, Muller W, Wagner N, Schon MP, Puddington L (1999) The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med 189:1631-1638.
63. Lehmann J, Huehn J, de la RM, Maszyna F, Kretschmer U, Krenn V, Brunner M, Scheffold A, Hamann A (2002) Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25? as well as. Proc Natl Acad Sci USA 99:13031-13036.
64. Ludviksson BR, Strober W, Nishikomori R, Hasan SK, Ehrhardt RO (1999) Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice. J Immunol 162:4975-4982.
65. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445.
66. Maruyama S, Kageyama S, Sugiura T, Suzuki M (2007) An orally active Alpha4 integrin antagonist Ajm300 attenuates inflammatory cell infiltration and exacerbation of DSS-induced chronic colitis in rats. Gastroenterology 132:A229.
67. McDonald SA, Palmen MJ, Van Rees EP, MacDonald TT (1997) Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology 91:73-80.
68. McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA (2003) Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 10:150-158.
69. Millennium Pharmaceuticals, Inc (2008) Phase 2 study of the safety and efficacy of LDP-02 in mildly to moderately active Crohn's patients. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00655135. Accessed on 8 April 2008.
70. Millennium Pharmaceuticals, Inc (2010a) Long term safety of MLN0002 in patients with ulcerative colitis and Crohn's Disease. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00619489. Accessed on 22 December 2010.
71. Millennium Pharmaceuticals, Inc (2010b) Study of MLN0002 following multiple intravenous doses in patients with ulcerative colitis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01177228. Accessed on 19 August 2010.
72. Millennium Pharmaceuticals, Inc (2011a) An open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn's disease. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00790933. Accessed on 13 July 2011.
73. Millennium Pharmaceuticals, Inc (2011b) Study of vedolizumab (MLN0002) in patients with moderate to severe Crohn's disease. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00783692. Accessed on 17 March 2011.
74. Millennium Pharmaceuticals, Inc (2011c) Study of vedolizumab (MLN0002) in patients with moderate to severe ulcerative colitis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00783718. Accessed on 17 March 2011.
75. Millennium Pharmaceuticals, Inc (2011d) Study of vedolizumab in patients with moderate to severe Crohn's Disease. ClinicalTrials. gov. http://ClinicalTrials.gov/show/NCT01224171. Accessed on 5 July 2011.
76. Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK (2006a) Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 23:1427-1434.
77. Miner PB Jr, Wedel MK, Xia S, Baker BF (2006b) Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, activecontrolled trial. Aliment Pharmacol Ther 23:1403-1413.
78. Mora JR (2008) Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. Inflamm Bowel Dis 14:275-289.
79. Muller WA (2003) Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 24:327-334.
80. Nakamura S, Ohtani H, Watanabe Y, Fukushima K, Matsumoto T, Kitano A, Kobayashi K, Nagura H (1993) In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 69:77-85.
81. Olson TS, Bamias G, Naganuma M, Rivera-Nieves J, Burcin TL, Ross W, Morris MA, Pizarro TT, Ernst PB, Cominelli F, Ley K (2004) Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 114:389-398.
82. Oshitani N, Campbell A, Bloom S, Kitano A, Kobayashi K, Jewell DP (1995) Adhesion molecule expression on vascular endothelium and nitroblue tetrazolium reducing activity in human colonic mucosa. Scand J Gastroenterol 30:915-920.
83. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D (2000) A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 165:2943-2949.
84. Panes J, Granger DN (1996) Neutrophils generate oxygen free radicals in rat mesenteric microcirculation after abdominal irradiation. Gastroenterology 111:981-989.
85. Panes J, Granger DN (1998) Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 114:1066-1090.
86. Panes J, Perry M, Granger DN (1999) Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 126:537-550.
87. Panes J, Perry MA, Anderson DC, Manning A, Leone B, Cepinskas G, Rosenbloom CL, Miyasaka M, Kvietys PR, Granger DN (1995) Regional differences in constitutive and induced ICAM-1 expression in vivo. Am J Physiol 269:H1955-H1964.
88. Pang M, Abe T, Fujihara T, Mori S, Tsuzaka K, Amano K, Koide J, Takeuchi T (1998) Up-regulation of alphaEbeta7, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement. Arthritis Rheum 41:1456-1463.
89. Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6:633-643.
90. Peyrin-Biroulet L, Deltenre P, de SN, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6:644-653.
91. Pfizer (2009) A study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00928681. Accessed on 25 June 2009.
92. Pfizer (2011a) Evaluation of the effect of the study drug (PF- 00547659) on white blood cells circulating in the spinal fluid around the brain and spinal column in patients with Crohn's disease who have failed or did not tolerate anti-TNF treatment. ClinicalTrial.gov. http://ClinicalTrials.gov/show/ NCT01387594 Accessed on 30 June 2011.
93. Pfizer (2011b) Study to test whether PF-00547659 is safe and improves disease symptoms in patients with Crohn's disease that have not responded to other treatments. ClinicalTrials.gov. http://ClinicalTrials.gov/show/ NCT01276509. Accessed on 15 July 2011.
94. Pfizer (2011c) This is a safety study to monitor longer-term treatment with PF-00547659. ClinicalTrials.gov. http://ClinicalTrials.gov/show/ NCT01298492. Accessed on 5 June 2011.
95. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ (1997) Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4? T cells. J Immunol 158:2099- 2106.
96. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW (2000) Ligand binding to integrins. J Biol Chem 275:21785-21788.
97. Pooley N, Ghosh L, Sharon P (1995) Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 40:219-225.
98. Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S (2009) Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 157:281-293.
99. Rihs S, Walker C, Virchow JC Jr, Boer C, Kroegel C, Giri SN, Braun RK (1996) Differential expression of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: regulation by alpha 4 beta 1-integrin crosslinking and TGF-beta. Am J Respir Cell Mol Biol 15:600-610.
100. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F (2006) Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 131:1518-1529.
101. Rot A, von Andrian UH (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891-928.
102. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgan DC, Bressler B, Schreiber S, Mansfield JC, Williams M, Keir ME, Arian BS, Luca D, O'Bryne S (2011) A phase I study of rHuMab Beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology 140:S125.
103. Salmi M, Jalkanen S (2005) Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev 206:100- 113.
104. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van DS, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353:1912-1925.
105. Sandborn WJ, Yednock TA (2003) Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98:2372-2382.
106. Sans M, Panes J, Ardite E, Elizalde JI, Arce Y, Elena M, Palacin A, Fernandez-Checa JC, Anderson DC, Lobb R, Pique JM (1999) VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116:874- 883.
107. Schlickum S, Sennefelder H, Friedrich M, Harms G, Lohse MJ, Kilshaw P, Schon MP (2008) Integrin alpha E(CD103)beta 7 influences cellular shape and motility in a ligand-dependent fashion. Blood 112:619-625.
108. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM (2001) Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120:1339-1346.
109. Schweighoffer T, Tanaka Y, Tidswell M, Erle DJ, Horgan KJ, Luce GE, Lazarovits AI, Buck D, Shaw S (1993) Selective expression of integrin alpha 4 beta 7 on a subset of human CD4? memory T cells with Hallmarks of gut-trophism. J Immunol 151:717-729.
110. Shimaoka M, Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2:703-716.
111. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330:864-875.
112. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J (2000) VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSSinduced colitis in mice. Lab Invest 80:1541-1551.
113. Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M (2011) A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 162:1855-1870.
114. Sugiura T, Kageyama S, Kuribayashi K, Suzuki M (2009) An orally active alpha4 integrin antagonist AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL- 10 deficient CD4? T cells in mice. Gastroenterology 136:A402.
115. Takazoe M, Watanabe M, Kawaguchi T, Matsumoto T, Oshitani N, Hiwatashi N, Hibi T (2009) Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease-a randomized, double-blind, placebo-controlled trial. Gastroenterology 136:A181.
116. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425-437.
117. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132:1672-1683.
118. Tidswell M, Pachynski R, Wu SW, Qiu SQ, Dunham E, Cochran N, Briskin MJ, Kilshaw PJ, Lazarovits AI, Andrew DP, Butcher EC, Yednock TA, Erle DJ (1997) Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1. J Immunol 159:1497-1505.
119. Trollmo C, Nilsson IM, Sollerman C, Tarkowski A (1996) Expression of the mucosal lymphocyte integrin alpha E beta 7 and its ligand E-cadherin in the synovium of patients with rheumatoid arthritis. Scand J Immunol 44:293-298.
120. Ungashe SB, Wei Z, Rubas W, Lai NL, Ertl L, Baumgart T, Wang H L, Miao ZH, Hor SY, Premack B, Moore J, Sullivan E, Pennell A, Keshav S, Sanders M, Howard M, Wright JJK, Bekker P, Schall TJ (2008) MEDI 167-discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B. Abstr Pap Am Chem Soc 235.
121. Uss E, Rowshani AT, Hooibrink B, Lardy NM, van Lier RA, ten Berge IJ (2006) CD103 is a marker for alloantigen-induced regulatory CD8? T cells. J Immunol 177:2775-2783.
122. Van Assche G, Van RM, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362-368.
123. van der Flier A, Sonnenberg A (2001) Function and interactions of integrins. Cell Tissue Res 305:285-298.
124. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr (2006) A phase II dose ranging, double-blind, placebocontrolled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23:1415-1425.
125. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, Strauch U, Burgess G, Spanton J, Martin SW, Niezychowski W (2011) The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 60:1068-1075.
126. von Andrian UH, Engelhardt B (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348:68-72.
127. von Andrian UH, Mackay CR (2000) T-cell function and migration. Two sides of the same coin. N Engl J Med 343:1020-1034.
128. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold M ET, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJK, Schall TJ (2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 335(1):61-69.
129. Williamson KD, Hetzel DJ, Badov D, Connell W, Edwards S, Gibson PR, Leong RWL, Macrae F, Mitchell B, Radford-Smith G, Bekker P, Schall TJ (2010) One-year results from protect-1 study of intestine-specific chemokine receptor antagonist CCX282-B in Crohn's disease. J Gastroenterol Hepatol 25:A96.
130. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114:1133-1142.
131. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR, ISIS 2302-CS9 Investigators (2002) Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51:30-36.
132. Yadav R, Larbi KY, Young RE, Nourshargh S (2003) Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 90:598-606.
133. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933.
134. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.
135. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34? hematopoietic progenitor cells in humans. Blood 111:3893-3895.